Verrica Pharmaceuticals (VRCA) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Verrica Pharmaceuticals (NASDAQ:VRCA) from a hold rating to a sell rating in a research report released on Thursday.

According to Zacks, “Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company. It develops and manufactures pharmaceutical products for the treatment of skin diseases such as molluscum contagiosum and dermatology. Verrica Pharmaceuticals, Inc. is based in PA, United States. “

Shares of VRCA stock traded up $0.06 on Thursday, hitting $10.31. The stock had a trading volume of 523 shares, compared to its average volume of 40,487. Verrica Pharmaceuticals has a one year low of $10.12 and a one year high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Wednesday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, sell-side analysts anticipate that Verrica Pharmaceuticals will post -1.17 EPS for the current fiscal year.

In related news, COO Linda Palczuk bought 2,500 shares of the business’s stock in a transaction on Monday, September 17th. The shares were bought at an average price of $16.52 per share, for a total transaction of $41,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul B. Manning bought 70,200 shares of the business’s stock in a transaction on Tuesday, November 13th. The stock was bought at an average price of $14.15 per share, for a total transaction of $993,330.00. The disclosure for this purchase can be found here.

Hedge funds have recently modified their holdings of the company. Fosun International Ltd purchased a new stake in shares of Verrica Pharmaceuticals during the second quarter worth about $15,705,000. Asymmetry Capital Management L.P. grew its stake in shares of Verrica Pharmaceuticals by 28.1% during the third quarter. Asymmetry Capital Management L.P. now owns 76,885 shares of the company’s stock worth $1,249,000 after acquiring an additional 16,885 shares during the last quarter. Dean Capital Investments Management LLC purchased a new stake in shares of Verrica Pharmaceuticals during the second quarter worth about $676,000. Gilder Gagnon Howe & Co. LLC grew its stake in shares of Verrica Pharmaceuticals by 12.4% during the third quarter. Gilder Gagnon Howe & Co. LLC now owns 167,574 shares of the company’s stock worth $2,723,000 after acquiring an additional 18,530 shares during the last quarter. Finally, FMR LLC purchased a new stake in shares of Verrica Pharmaceuticals during the second quarter worth about $21,703,000. Institutional investors and hedge funds own 32.07% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Featured Story: What is Cost of Capital?

Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply